Mast Cell-Mediated Inhibition of Abdominal Neutrophil Inflammation by a PEGylated TLR7 Ligand
Figure 5
Tolerimod1 reduced the severity of DSS-induced colitis (a and b) DSS-colitis mice ( per group) were treated with 200 nmol Tolerimod1 subcutaneously (SC) or orally (PO) for 7 days. Disease activity index (a) and body weight loss (b) were evaluated. (c) The colons isolated from mice treated s.c. with vehicle or Tolerimod1 were stained with hematoxylin or eosin, or immunostained for MPO. Data shown are mean ± SEM and are pooled from 2 independent experiments that showed similar trends. *Denotes by one-way ANOVA with Dunnett’s post hoc testing compared to the vehicle-treated group.
